65 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
GSK vs. VRTX: Which Stock Should Value Investors Buy Now? https://www.zacks.com/stock/news/2193083/gsk-vs-vrtx-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2193083 Dec 04, 2023 - GSK vs. VRTX: Which Stock Is the Better Value Option?
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year? https://www.zacks.com/stock/news/2192952/is-gsk-plc-sponsored-adr-gsk-stock-outpacing-its-medical-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2192952 Dec 04, 2023 - Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick https://www.zacks.com/stock/news/2196150/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2196150 Dec 11, 2023 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK (GSK) Beats Stock Market Upswing: What Investors Need to Know https://www.zacks.com/stock/news/2198311/gsk-gsk-beats-stock-market-upswing-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2198311 Dec 14, 2023 - GSK (GSK) concluded the recent trading session at $36.98, signifying a +0.65% move from its prior day's close.
5 Big Drug Stocks That May Continue to Outperform in 2024 https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316 Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
GSK (GSK) Rises Higher Than Market: Key Facts https://www.zacks.com/stock/news/2202904/gsk-gsk-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2202904 Dec 27, 2023 - In the most recent trading session, GSK (GSK) closed at $37.10, indicating a +0.24% shift from the previous trading day.
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092 Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960 Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth https://www.zacks.com/stock/news/2215035/gsk-gsk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215035 Jan 24, 2024 - Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store? https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142 Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.

Pages: 1234567

<<<Page 5>